Trimebutin is a synthetic agonist of peripheral opioid receptors m, d and k. The mechanism of action is a direct effect on the smooth muscles of the digestive tract and the regulation of motility disorders without affecting the central nervous system. Unlike other opioids, trimebutin is not characterized by selectivity for any of the three types of receptors, due to which it can both enhance and inhibit peristalsis. The process of normalization of motility begins 30 minutes after the use of the drug.